Archive for January, 2010

Veggies in Pregnancy Lowers Child’s Diabetes Risk

Sunday, January 31st, 2010

Children born to mothers who ate plenty of vegetables during pregnancy are less likely to have type 1 diabetes, Swedish researchers say.

“This is the first study to show a link between vegetable intake during pregnancy and the risk of the child subsequently developing type 1 diabetes, but more studies of various kinds will be needed before we can say anything definitive,” study author Hilde Brekke, a clinical nutritionist at the Sahlgrenska Academy at the University of Gothenburg, said in a news release from the university.

Brekke and colleagues studied 6,000 5-year-olds and found that 3 percent either had fully developed type 1 diabetes or had elevated levels of antibodies that indicate a risk of developing the disease. The risk was twice as high in children whose mothers rarely ate vegetables during pregnancy, and lowest among children whose mothers ate vegetables every day of their pregnancy.

The study was recently published online in the journal Pediatric Diabetes.

“We cannot say with certainty on the basis of this study that it’s the vegetables themselves that have this protective effect, but other factors related to vegetable intake, such as the mother’s standard of education, do not seem to explain the link,” Brekke said. “Nor can this protection be explained by other measured dietary factors or other known risk factors.”

While it’s not known what actually causes type 1 diabetes, factors believed to play a role include immunological mechanisms, environmental toxins and genetic variations. Type 1 diabetes occurs throughout the world but is most common in Finland and Sweden.

Whooping Cough Immunity Lasts 30 Years or More

Sunday, January 24th, 2010

Exposure to whooping cough will provide immunity for an average of three decades, new research suggests.

Doctors had previously thought that immunity lasted for much less time. But the new study, by researchers based at the University of Michigan and the University of New Mexico, rebuts that assumption.

Whooping cough, also known as pertussis, has become more common in the United States and elsewhere since the 1980s. Some health experts have thought that immunity is wearing off for people who’d been vaccinated or had been infected by the disease.

For the study, researchers used medical data from England and Wales from before a vaccine was available (1945-1957) as well as later (1958-1972). They created a mathematical model to determine how long immunity lasted after people were exposed naturally to the disease.

They found that immunity after natural infection lasts for at least three decades, on average, and maybe even as long as 70 years. The study suggests that people who lose some of their immunity might still have some protection and even gain more immunity when they’re exposed again to whooping cough.

“This is surprising because clinical epidemiologists currently believe the duration of pertussis immunity is somewhere between four and 20 years,” study co-author Pejman Rohani, of the University of Georgia, said in a news release from the publisher of PLoS Pathogens. The findings are published online Oct. 30 in the journal.

But there are caveats. “It’s worth pointing out that in the past 20 years or so, the nature of the vaccines that have been used has changed quite fundamentally,” Rohani said. “The data we’re using are from a time when a whole-cell vaccine was in use. Now an acellular vaccine, which stimulates a different part of the immune system, is typically used, especially in North America.”

Better Drug Emerges for Steroid-Induced Bone Loss

Sunday, January 17th, 2010

The drug teriparatide is better at increasing bone density and reducing vertebral fractures in patients with glucocorticoid-induced osteoporosis than the drug alendronate, a new study finds.

Glucocorticoids are steroid hormones produced in the body or contained in drugs that are used to control inflammation in patients with autoimmune diseases, such as rheumatoid arthritis, lupus and Crohn’s disease, as well as inflammatory conditions such as asthma. Glucocorticoid-induced osteoporosis can occur in people taking steroid medications such as prednisone, prednisolone, dexamethasone and cortisone, according to background information provided in a news release about the study.

The study participants included 428 patients, aged 22 to 89, with confirmed osteoporosis who had received more than 5 milligrams a day of prednisone or the equivalent for more than three months. For the study, 150 patients were randomly assigned to receive 20 micrograms a day of injectable teriparatide plus oral placebo, and 144 patients received 10 milligrams a day of oral alendronate plus injectable placebo. All the participants received supplements of calcium (1,000 milligrams a day) and vitamin D (800 International Units a day).

After 36 months, lumbar spine bone mineral density was 11 percent higher than at the start of the study in the teriparatide group compared with 5.3 percent higher in the alendronate group, the researchers found. Bone mineral density improvement for total hip was 5.2 percent in the teriparatide group versus 2.7 percent in the alendronate group, and 6.3 percent versus 3.4 percent, respectively, in the femoral neck.

Patients in the teriparatide group had fewer vertebral fractures (1.7 percent) than those in the alendronate group (7.7 percent) and also had higher levels of calcium concentrations (21 percent versus 7 percent), according to the study findings published in the November issue of the journal Arthritis & Rheumatism.

A significant number of individuals are regularly treated with steroids to control inflammation, “which puts them at risk for developing osteoporosis. A need for therapies that mitigate this side effect of steroid use and substantially improve bone mass is vital,” study leader Dr. Kenneth Saag, of the University of Alabama, said in a news release from the journal’s publisher.

“Our research shows that teriparatide is a safe and effective treatment for patients with steroid-induced [osteoporosis] and should be considered as a therapeutic option for those at high risk of bone fracture,” he concluded.

Cholesterol Drugs May Help Prevent Flu Deaths

Sunday, January 10th, 2010

Statins, frequently used to cut cholesterol levels, may also help prevent death from severe flu, a new study suggests.

According to the researchers, a growing body of evidence suggests that statins — which include medicines such as Lipitor, Crestor and Zocor — can reduce death from severe infections. Whether they help with flu, however, has been more uncertain.

“Statins may have a role in reducing mortality from influenza, but our findings do not justify broader use of statins without confirming these findings in the setting of randomized controlled trials,” said study author Dr. Ann R. Thomas, from the Emerging Infections Program at the Oregon Department of Human Services Public Health Division in Portland.

“Statins may have a benefit, in conjunction with vaccine and antivirals, in reducing morbidity and mortality associated with influenza, likely due to their effect of reducing the body’s inflammatory response to influenza infection,” she added.

The results of the study are to be presented Friday at the Infectious Diseases Society of America annual meeting in Philadelphia.

For the study, Thomas’ team looked at the outcomes of hospitalized influenza patients over two flu seasons.

The researchers found that patients who were taking statins were more likely to be older, male, white or Asian with underlying health conditions such as cardiovascular disease. In addition, they were more likely to have had a flu shot.

While those with cardiovascular disease were more likely to die, those who received statins while in the hospital were less likely to die.

Whether statins are also effective in preventing deaths from the H1N1 swine flu is not known, Thomas said. “Our data are from the 2007-2008 influenza season, well before novel H1N1 emerged, so no one knows for sure if statins would reduce mortality from H1N1,” she said.

“However, since the likely mechanism of statins in reducing mortality is their general effect of down-regulating the immune system, it is plausible that statins might be useful in treating influenza infections due to novel H1N1,” she noted.

Infectious diseases expert Dr. Marc Siegel, an associate professor of medicine at New York University School of Medicine in New York City, said that the study “is of limited value.”

Siegel believes it’s statins’ ability to prevent death from heart disease and not any benefit against flu that results in fewer deaths among those taking these drugs.

“Influenza increases your risk of dying from heart disease. At the same time, statins reduce your risk of dying from heart disease. So, it’s not surprising to find that there are fewer deaths among those taking statins,” Siegel said.

“You can’t conclude from this study that people with influenza should take statins,” he said. “Statins are protective in a situation where the heart is at risk, even influenza — that, I’ll buy.”